Clinical trials: Benign Meningioma
Intraspinal Tumor, Juxtamedullary Tumor
Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors
Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary…
- Trial name
- EURJMT (NCT07056023)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Muenster
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Brain Tumor
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
- Trial name
- NCT03220646
- Testing
- abemaciclib
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Brain Tumor, Glioma
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain.
- Conditions
- Primary Brain Tumor, Glioma, Meningioma, Schwannoma
- Trial name
- NCT05576103
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Jona Hattangadi-Gluth
Brain Tumor Adult, Brain Tumor Benign
Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors
Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura) to reach the tumor.
- Conditions
- Brain Tumor Adult, Brain Tumor Benign, CerebroSpinal Fluid (CSF) Leak, Craniotomy
- Trial name
- CSF-IMR (NCT07411690)
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Warsaw
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Tranexamic Acid, Intraoperative Blood Loss
Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection
Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and higher mortality.
- Conditions
- Tranexamic Acid, Intraoperative Blood Loss, Meningioma
- Trial name
- NCT05230381
- Testing
- Continous infusion, Single infusion
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Beijing Tiantan Hospital
Meningioma
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
This prospective single-center study aims to evaluate the feasibility and clinical utility of three-dimensional magnetic resonance elastography (3D MRE) in assessing tumor stiffness and adhesion in patients with meningioma…
- Trial name
- NCT06955208
- Testing
- Magnetic Resonance Elastography, Intraoperative Assessment and Recording
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Recurrent Atypical/malignant Meningioma
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed…
- Trial name
- NCT04501705
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Sanbo Brain Hospital
CNS Cancer, Meningioma
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma.
- Conditions
- CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma
- Trial name
- NCT00589784
- Testing
- Sunitinib
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
NF2-related Schwannomatosis, NF2
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2).
- Conditions
- NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma
- Trial name
- NCT07708285
- Testing
- Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Hemostasis, Meningioma Surgery
Phase IV Bioseal Study in Brain Tumor Surgery
The objective of this study is to observe the clinical utility and performance of Bioseal when used as an adjunct to hemostasis versus Standard of Care (SoC) in elective meningioma surgery.
- Trial name
- NCT02034799
- Testing
- Bioseal Fibrin Sealant, Standard of Care (SoC)
- Where
- 7 sites in China
- Volunteers
- 256 people
- Sponsor
- Ethicon, Inc.
Meningiomas
Effects of Scalp Nerve Blocks on Systemic Inflammation
Patients undergoing meningeoma resection surgery will be randomly assigned to two groups. One group will receive scalp nerve blocks with 0.5% ropivacaine, whereas the other group will receive scalp nerve blocks with 0.9% saline…
- Trial name
- NCT02939833
- Testing
- Scalp Nerve Blocks With Ropivacaine, Scalp Nerve Blocks With Saline
- Where
- China
- Volunteers
- 160 people
- Sponsor
- RenJi Hospital
Meningioma
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
Patients undergoing elective meningeoma resection surgery will be randomly assigned to one of the following two groups. After anesthesia induction but before skull-pin insertion, one group will receive scalp nerve blocks with…
- Trial name
- NCT03648034
- Testing
- ropivacaine, saline
- Where
- China
- Volunteers
- 144 people
- Sponsor
- RenJi Hospital
Spinal Metastases, Vertebral Metastases
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma
- Trial name
- NCT01347307
- Testing
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mercy Research
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)